The Gemeinsame Bundesausschuss (G-BA), Germany’s Federal Joint Committee, has initiated a re-evaluation of Trastuzumab deruxtecan, a pharmaceutical treatment for advanced HER2-positive adenocarcinoma of the stomach or gastro-esophageal junction (GEJ). This decision, made on July 3, 2025, responds to a formal request submitted by the drug’s manufacturer on May 8, 2025, seeking a renewed benefit assessment under §35a Abs. 5 of the Fifth Book of the Social Code (SGB V).
Scope of the Re-Evaluation
The re-assessment focuses specifically on the use of Enhertu as a monotherapy for adult patients with advanced HER2-positive adenocarcinoma of the stomach or GEJ who have previously undergone a Trastuzumab-based therapy. The evaluation aims to compare the drug’s efficacy against established therapies such as Docetaxel, Irinotecan, and Paclitaxel, referencing the Arzneimittel-Richtlinie guidelines. The G-BA will utilize data from the DESTINY-Gastric0-4 trial, a Phase III study comparing the drug against Ramucirumab combined with Paclitaxel, to inform its assessment.
Procedural Requirements and Deadlines
The pharmaceutical company is required to compile and submit comprehensive evidence, including previously evaluated data, within three months of the G-BA’s decision. This dossier must adhere to the G-BA’s documentation standards, ensuring all relevant clinical and therapeutic data is thoroughly presented for the specific patient population under review. The process underscores the G-BA’s commitment to maintaining up-to-date evaluations based on the latest scientific findings.
Inference:
- Trastuzumab deruxtecan’s efficacy is being directly compared to conventional therapies, potentially impacting future treatment protocols.
- The inclusion of the DESTINY-Gastric0-4 study data suggests a robust evidence base for the re-evaluation.
- Strict deadlines emphasize the urgency and importance of timely decision-making in healthcare assessments.
The decision by the G-BA highlights the dynamic nature of pharmaceutical evaluations in Germany, ensuring that patient treatments remain aligned with the latest medical advancements and evidence-based practices. By mandating a thorough re-assessment of Trastuzumab deruxtecan, the committee aims to validate its therapeutic benefits and cost-effectiveness within the specified patient group. This process not only safeguards the quality of care but also ensures that healthcare resources are utilized efficiently.
As the re-evaluation progresses, stakeholders anticipate that the findings will provide clear guidance on the integration of Trastuzumab deruxtecan into standard treatment regimens. This move reflects a broader trend towards personalized medicine, where treatments are increasingly tailored to specific patient profiles based on comprehensive clinical data. Ultimately, the G-BA’s actions are set to enhance the precision and efficacy of cancer therapies available to patients in Germany.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
